Pair of COVID-19 vaccine candidates move on to next trial phases

Jul 20, 2020 - 02:39 PM
COVID19 Web Sized

A COVID-19 trial vaccine developed by the University of Oxford and AstraZeneca produced neutralizing antibody responses in patients with SARS-CoV-2, according to a study published July 20 in The Lancet. An immune response was detected in 32 of 35 participants after one dose and in all participants after a booster dose.

The trial will now proceed to phases two and three. Oxford/AstraZeneca in May announced it will provide the U.S. with 300 million initial doses and the U.K. 100 million initial doses this fall.

In a separate vaccine study by CanSino Biologics, also released today, a phase two test in Wuhan, China, showed an immunity response in 508 participants. The study said healthy adults may only need one dose, while older adults may need two to induce a better immune response. Results showed minimal adverse reactions; the candidate will now move to phase three testing.

Related News Articles

Headline
FDA authorizes combination tests for flu, COVID-19
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…
Headline
CDC: COVID-19 surging across the U.S.
The Centers for Disease Control and Prevention's COVID-19 data tracker shows an 18.1% test positivity rate for the week ending Aug. 10, the highest it has been…
Headline
CDC issues advisory on increased parvovirus B19 cases in the U.S. 
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S. Parvovirus B19 is a…
Blog
RAND 5.0 – The Health Policy Equivalent of Groundhog Day
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
CDC encourages older adults to get additional COVID-19 vaccine dose 
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
NASEM releases evidence review on COVID-19 vaccine safety
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…